Halozyme Therapeutics — Aug 5, 2025 release

Financial Outlook for 2025 The Company is raising its financial guidance for 2025. Note that the guidance reflects tariffs that are currently implemented. For the full year 2025, the Company expects: • Total revenue of $1,275 million to $1,355 million, representing growth of 26% to 33% over 2024 total revenue, primarily driven by increases in royalty revenue. Revenue from royalties of $825 million to $860 million, representing growth of 44% to 51% over 2024. • Adjusted EBITDA of $865 million to $915 million, representing growth of 37% to 45% over 2024. • Non-GAAP diluted earnings per share of $6.00 to $6.40, representing growth of 42% to 51% over 2024. The Company’s earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2025 Financial Guidance   Previous Guidance Range New Guidance Range Total Revenue $1,200 to $1,280 million $1,275 to $1,355 million Royalty Revenue $750 to $785 million $825 to $860 million Adjusted EBITDA $790 to $840 million $865 to $915 million Non-GAAP Diluted EPS $5.30 to $5.70 $6.00 to $6.40 1 Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release. Webcast and Conference Call Halozyme will host its Qu